Prevalence of antiphospholipid and antiplatelet antibodies in human immunodeficiency virus (HIV)-infected Chilean patients

✍ Scribed by Iván Palomo; Marcelo Alarcón; Cecilia Sepulveda; Jaime Pereira; Ricardo Espinola; Silvia Pierangeli

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 106 KB
• Volume: 17
• Category: Article
• ISSN: 0887-8013
• DOI: 10.1002/jcla.10093

✦ Synopsis

Abstract

Antiphospholipid (aPL) and antiplatelet (aPlt) antibodies, found in patients with autoimmune diseases, are also detected in infectious diseases. The purpose of this study was to examine the prevalence of these antibodies in HIV patients and to evaluate an association of these antibodies with thrombocytopenia and/or thrombosis. Sixty‐three HIV‐seropositive patients and 52 normal controls were studied. Anti‐cardiolipin (aCL), anti‐β~2~ glycoprotein I (anti‐β~2~GPI), and antiprothrombin (aPT) antibodies were determined and the lupus anticoagulant (LA) test was performed. Antiplatelet antibodies (aPlt) were also determined. Seven out of 63 (12.7%) HIV patients were positive for aCL, four of 63 (6.3%) for anti‐β~2~GPI, and five of 63 (7.9%) for aPT. No patients studied were LA positive. Six out of 63 (9.5%) patients were positive for aPlt. One of them showed weak reactivity for GPIb‐IX. The platelet count of patients (202±63×10^3^ platelets/μL) was significantly lower than in the controls (343±6×10^3^ platelets/μL) (P<0.001). There was no correlation between the presence of aPL and/or aPlt and thrombocytopenia. Of the HIV‐infected patients, 22.2% presented aPL and 9.4% aPlt antibodies. In this study, the presence of aPL and aPlt antibodies was not associated with the development of thrombosis and/or thrombocytopenia. J. Clin. Lab. Anal. 17:209–215, 2003. © 2003 Wiley‐Liss, Inc.